» Articles » PMID: 33517895

Long Term Disease Burden Post-transplantation: Three Decades of Observations in 25 Hurler Patients Successfully Treated with Hematopoietic Stem Cell Transplantation (HSCT)

Overview
Publisher Biomed Central
Specialty General Medicine
Date 2021 Feb 1
PMID 33517895
Citations 19
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Mucopolysaccharidosis type I-Hurler syndrome (MPSI-H) is a lysosomal storage disease characterized by severe physical symptoms and cognitive decline. Early treatment with hematopoietic cell transplant (HSCT) is critical to the survival of these patients. While survival rates and short-term outcomes are known to be improved by HSCT, the long-term cognitive, adaptive and psychosocial functional outcomes of children with (MPSI-H) post-HSCT are not well documented. This manuscript focuses on retrospective long-term follow-up (7-33 years) of 25 MPSI-H patients, transplanted between 1986 and 2011.

Results: The median age at transplantation was 21 months (range 12-57 months). Except for one death, all successfully transplanted MPSI-H patients surviving at least 1 year after HSCT are alive to-date, with a median age of 21 years (range 8-36 years) at the last follow-up evaluation. A majority of HSCT grafts were bone marrow transplants (BMT), resulting in durable full chimerism in 18 (72%). Pre-HSCT, the onset of first symptoms occurred very early, at a median age of 3 months (range birth-16 months). The most prevalent symptoms before MPSI-H diagnosis involved progressive dysostosis multiplex; almost all patients suffered from hip dysplasia and thoracolumbar spine Kyphosis. Despite HSCT, considerable residual disease burden and ensuing corrective surgical interventions were observed in all, and at every decade of follow-up post HSCT. Late-onset psychiatric manifestations were significant (n = 17 patients; 68%), including depression in 13 patients at a median onset age of 18 years (range 13-31 years), hyperactivity and attention deficit disorder (n = 4), and multiple acute psychotic episodes (APE), independent of depression observed (n = 3) at a median onset age of 18 years (range 17-31 years). The adult Welscher Intelligence Scale results (n = 16) were heterogenous across the four scale dimensions; overall lower scores were observed on both working memory index (median WMI = 69.5) and processing speed index (median PSI = 65), whereas verbal comprehension index (median VCI = 79) and perceptual reasoning index (median PRI = 74) were higher.

Conclusion: With advanced treatment options, MPSI-H are living into 3rd and 4th decades of life, however not disease free and with poor adaptation. Residual disease (loss of mobility, limited gross and fine motor skills; low cognitive ability; suboptimal cardiopulmonary function, vision and hearing) negatively impacts the quality of life and psychosocial functioning of affected individuals.

Citing Articles

Current and Emerging Therapies for Lysosomal Storage Disorders.

Abelleyra Lastoria D, Keynes S, Hughes D Drugs. 2025; 85(2):171-192.

PMID: 39826077 DOI: 10.1007/s40265-025-02145-5.


A kaleidoscopic view of extracellular vesicles in lysosomal storage disorders.

Hegeman C, de Jong O, Lorenowicz M Extracell Vesicles Circ Nucl Acids. 2024; 3(4):393-421.

PMID: 39697359 PMC: 11651879. DOI: 10.20517/evcna.2022.41.


Body Height of MPS I and II Patients after Hematopoietic Stem Cell Transplantation: The Impact of Dermatan Sulphate.

Lipinski P, Rozdzynska-Swiatkowska A, Lugowska A, Marucha J, Drabko K, Tylki-Szymanska A Diagnostics (Basel). 2024; 14(17).

PMID: 39272740 PMC: 11394317. DOI: 10.3390/diagnostics14171956.


Hematopoietic stem cell gene therapy improves outcomes in a clinically relevant mouse model of multiple sulfatase deficiency.

Pham V, Tricoli L, Hong X, Wongkittichote P, Castruccio Castracani C, Guerra A Mol Ther. 2024; 32(11):3829-3846.

PMID: 39169621 PMC: 11573602. DOI: 10.1016/j.ymthe.2024.08.015.


Gene therapy for ultrarare diseases: a geneticist's perspective.

Hwu W J Biomed Sci. 2024; 31(1):79.

PMID: 39138523 PMC: 11321167. DOI: 10.1186/s12929-024-01070-1.


References
1.
Muenzer J, Wraith J, Clarke L . Mucopolysaccharidosis I: management and treatment guidelines. Pediatrics. 2009; 123(1):19-29. DOI: 10.1542/peds.2008-0416. View

2.
Shapiro E, Guler O, Rudser K, Delaney K, Bjoraker K, Whitley C . An exploratory study of brain function and structure in mucopolysaccharidosis type I: long term observations following hematopoietic cell transplantation (HCT). Mol Genet Metab. 2012; 107(1-2):116-21. PMC: 3444648. DOI: 10.1016/j.ymgme.2012.07.016. View

3.
Prasad V, Kurtzberg J . Transplant outcomes in mucopolysaccharidoses. Semin Hematol. 2010; 47(1):59-69. DOI: 10.1053/j.seminhematol.2009.10.008. View

4.
Sifuentes M, Doroshow R, Hoft R, Mason G, Walot I, Diament M . A follow-up study of MPS I patients treated with laronidase enzyme replacement therapy for 6 years. Mol Genet Metab. 2006; 90(2):171-80. DOI: 10.1016/j.ymgme.2006.08.007. View

5.
Soni-Jaiswal A, Mercer J, Jones S, Bruce I, Callery P . Mucopolysaccharidosis I; Parental beliefs about the impact of disease on the quality of life of their children. Orphanet J Rare Dis. 2016; 11(1):96. PMC: 4942895. DOI: 10.1186/s13023-016-0478-z. View